BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Strontium ranelate containing medicinal products: risk of cardiavascular side effects

2014.05.19

Active substance: strontium ranelate

19.05.2014 - European Commission final decision

The BfArM issues information on the implementing decision of the Commission within a European safety review in accordance with Article 20 of Regulation (EC-European Community) No. 726/2004.

24.02.2014 - CHMP opinion

The BfArM issues information on the CHMP's scientific conclusions within a European safety review in accordance with Article 20 of Regulation (EC) No. 726/2004.

Further information

For details regarding the procedure please click on the following link to the European Medicines Agency (EMA):

Protelos and Osseor